Phase3 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Double-blind, Parallel Group,Placebo-Controlled Study)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221620

Enrollment

132

Registered

2011-10-17

Start date

2011-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : TS-071 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Or

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Type 2 diabetes mellitus - HbA1c 6.5% to 10.0% etc.

Exclusion criteria

Exclusion criteria: - Except type 2 diabetes mellitus. - Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease. etc.

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
Blood-sugar level, etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026